Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
TEMPLE CITY, Calif., Nov. 15, 2016 -- Fulgent Genetics, Inc. (Nasdaq:FLGT) today announced that Ming Hsieh, Chairman and Chief Executive Officer, and Paul Kim, Chief Financial Officer, are scheduled to participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace hotel on Tuesday, November 29, 2016 at 10:00 AM Eastern Time.
The live audio webcast can be accessed in the Investor Relations section of the company’s website, www.fulgentgenetics.com. An audio replay of the webcast will remain available on the company’s website through December 29, 2016.
About Fulgent Genetics, Inc.
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive leaning software, advanced genetic diagnostic tools, and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy, and competitive turnaround times. The company believes its current test menus, which includes more than 18,000 single-gene tests and more than 250 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Contact: The Blueshirt Group Bob Jones, 212- 871-5570, [email protected]
